Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saloua Mrabet

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 28, 2022
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Johannes Lorscheider, Sandra Vukusic, et al.
JAMA Network Open|September 15, 2025
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis DisabilityJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2024
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort studyCathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, et al.
Therapeutic Advances in Neurological Disorders|December 30, 2025
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase RegistryEnrique Gomez-Figueroa, Patricia Orozco-Puga, Cynthia Patricia Corona-Vázquez, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 20, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumabNathaniel Lizak, Sifat Sharmin, Dana Horáková, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 28, 2022
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data networkAlessio Signori, Johannes Lorscheider, Sandra Vukusic, et al.
JAMA Network Open|September 15, 2025
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis DisabilityJessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, et al.
Computer Methods and Programs in Biomedicine|February 18, 2025
Explainable time-to-progression predictions in multiple sclerosisRobbe D'hondt, Klest Dedja, Sofie Aerts, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 3, 2024
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort studyCathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, et al.
Therapeutic Advances in Neurological Disorders|December 30, 2025
Real-world effectiveness of horizontal switching between disease-modifying therapies in multiple sclerosis: a retrospective analysis of the MSBase RegistryEnrique Gomez-Figueroa, Patricia Orozco-Puga, Cynthia Patricia Corona-Vázquez, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
JAMA Neurology|July 12, 2023
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple SclerosisTomas Kalincik, Sifat Sharmin, Izanne Roos, et al.
Pageof 6